Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Fishel

Clinical Cardiac Electrophysiology Atlantis, FL Medical Doctor

NPI 1679509517 CMS profile 257854

180 Jfk Dr, Suite 311, Atlantis, FL 33462

Open in the dashboard

General payments

$148,563

316 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$1,667,739

3 holdings reported · through program year 2025

Research they led as principal investigator

$383,132 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Robert Fishel of Atlantis, FL is reported in the CMS Open Payments database as having received $148,563 across 316 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $383,132 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $1,667,739 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46,319 40
2024 General $11,525 60
2023 General $18,686 77
2022 General $14,903 50
2021 General $1,256 16
2020 General $34,317 22
2019 General $21,558 51
2025 Ownership $595,621 1
2024 Ownership $595,621 1
2023 Ownership $476,497 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Fishel
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Robert Fishel were reported at $46,319. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Robert Fishel Clinical Cardiac Electrophysiology median Middle half National median
2019 $21,558 $2,361 $585–$8,260 $163
2020 $34,317 $993 $247–$4,351 $114
2021 $1,256 $1,185 $326–$4,739 $132
2022 $14,903 $2,073 $554–$6,789 $149
2023 $18,686 $2,568 $759–$8,159 $160
2024 $11,525 $2,557 $703–$7,403 $164
2025 $46,319 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biosense Webster, Inc. $82,369 127 payments
  2. Medical Device Business Services, Inc. $41,783 30 payments
  3. Braemar Manufacturing, LLC $10,026 2 payments
  4. Philips Electronics North America Corporation $5,705 8 payments
  5. Medtronic, Inc. $3,404 48 payments
  6. Medtronic Vascular, Inc. $1,379 21 payments
  7. Abbott Laboratories $962 34 payments
  8. Boston Scientific Corporation $662 5 payments
  9. Impulse Dynamics (USA) Inc. $488 4 payments
  10. Ge Healthcare $417 4 payments
  11. Other $1,369 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $129,107 36 payments
  2. Food and Beverage $16,950 268 payments
  3. Travel and Lodging $2,507 12 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $84,230 84 payments
  2. Carto 3 System $36,402 11 payments
  3. Cardiac Monitoring Suite $10,026 2 payments
  4. (7999) SRC Undivided $5,223 2 payments
  5. QDOT MICRO Catheter $1,247 14 payments
  6. Confidense $1,036 20 payments
  7. QDOT MICRO Catheter $890 9 payments
  8. OCTARAY MAPPING CATHETER $855 9 payments
  9. PENTARAY $797 12 payments
  10. CartoSound $521 11 payments
  11. Other $8,207 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

861

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$407,647

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

50.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 288 $283,400
Xarelto Rivaroxaban Brand 60 $62,246
Multaq Dronedarone Hcl Brand 19 $29,695
Mounjaro Tirzepatide Brand 16 $18,239
Flecainide Acetate Generic 172 $5,943
Toprol Xl Metoprolol Succinate Brand 13 $2,975
Dofetilide Generic 15 $2,316
Metoprolol Succinate Generic 99 $1,416
Amiodarone Hcl Generic 65 $822
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 24 $240

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$870,610

Medicare's payments for the services billed

Medicare patients

644

Average age 77

Services billed

7,059

223 women, 421 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 54%
Arthritis 54%
Heart failure 34%
Diabetes 30%
Chronic kidney disease 30%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $38
$38 — —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $21
$21 19 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $17
$17 288 —
RYBELSUS
  • Novo Nordisk Inc $7
$7 — —
Ozempic
  • Novo Nordisk Inc $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

316 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record